Scrambler therapy for noncancer neuropathic pain

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Salahadin Abdi ◽  
Matthew Chung ◽  
Giuseppe Marineo
Keyword(s):  
Neuropathic Pain ◽  
Scrambler Therapy

scholarly journals Differential response to scrambler therapy by neuropathic pain phenotypes

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Young Gi Min ◽  
Hyun Seok Baek ◽  
Kyoung-Min Lee ◽  
Yoon-Ho Hong
Keyword(s):  
Neuropathic Pain ◽  
Treatment Outcome ◽  
Rating Scale ◽  
Numerical Rating Scale ◽  
Brief Pain Inventory ◽  
Differential Response ◽  
Open Label ◽  
Numerical Rating ◽  
Scrambler Therapy ◽  
Post Hoc

AbstractScrambler therapy is a noninvasive electroanalgesia technique designed to remodulate the pain system. Despite growing evidence of its efficacy in patients with neuropathic pain, little is known about the clinical factors associated with treatment outcome. We conducted a prospective, open-label, single-arm trial to assess the efficacy and safety of scrambler therapy in patients with chronic neuropathic pain of various etiologies. A post-hoc analysis was performed to investigate whether cluster analysis of the Neuropathic Pain Symptom Inventory (NPSI) profiles could identify a subgroup of patients regarding neuropathic pain phenotype and treatment outcome. Scrambler therapy resulted in a significant decrease in the pain numerical rating scale (NRS) score over 2 weeks of treatment (least squares mean of percentage change from baseline, − 15%; 95% CI − 28% to − 2.4%; p < 0.001). The mean score of Brief Pain Inventory (BPI) interference subdimension was also significantly improved (p = 0.022), while the BPI pain composite score was not. Hierarchical clustering based on the NPSI profiles partitioned the patients into 3 clusters with distinct neuropathic pain phenotypes. Linear mixed-effects model analyses revealed differential response to scrambler therapy across clusters (p = 0.003, pain NRS; p = 0.072, BPI interference subdimension). Treatment response to scrambler therapy appears different depending on the neuropathic pain phenotypes, with more favorable outcomes in patients with preferentially paroxysmal pain rather than persistent pain. Further studies are warranted to confirm that capturing neuropathic pain phenotypes can optimize the use of scrambler therapy.

scholarly journals Differential Response to Scrambler Therapy by Neuropathic Pain Phenotypes

2021 ◽  
Author(s):  
Young Gi Min ◽  
Hyun Seok Baek ◽  
Kyoung-Min Lee ◽  
Yoon-Ho Hong
Keyword(s):  
Neuropathic Pain ◽  
Treatment Outcome ◽  
Rating Scale ◽  
Numerical Rating Scale ◽  
Brief Pain Inventory ◽  
Differential Response ◽  
Sensory Profile ◽  
Open Label ◽  
Numerical Rating ◽  
Scrambler Therapy

Abstract Scrambler therapy is a novel noninvasive electroanalgesia technique designed to remodulate the pain system. Despite growing evidence of its efficacy in patients with neuropathic pain, little is known about the clinical factors associated with treatment outcome. We conducted a prospective, open-label, single-arm trial to assess the efficacy and safety of scrambler therapy in patients with chronic neuropathic pain of various etiologies. A post-hoc analysis was performed to investigate whether cluster analysis of the Neuropathic Pain Symptom Inventory profiles could identify a subgroup of patients regarding neuropathic pain phenotype and treatment outcome. Scrambler therapy resulted in a significant decrease in the pain numerical rating scale (NRS) score over 2 weeks of treatment (least squares mean of percentage change from baseline, −15%; 95% CI, −28% to −2.4%; p < 0.001). The mean score of Brief Pain Inventory (BPI) interference subdimension was also significantly improved (p = 0.022), while the BPI pain composite score was not. Hierarchical clustering partitioned the patients into 3 clusters with distinct neuropathic pain phenotypes. Linear mixed-effects model analyses revealed differential response to scrambler therapy across clusters (p = 0.003, pain NRS; p = 0.072, BPI interference subdimension). Treatment response to scrambler therapy appears different depending on the pain-related sensory profile, with more favorable outcomes in patients with preferentially paroxysmal pain rather than persistent pain. Further studies are warranted to confirm that capturing neuropathic pain phenotypes can optimize the use of scrambler therapy.

A Review of Scrambler Therapy for Chronic Neuropathic Pain

2016 ◽  
Vol 5 (5) ◽  
Author(s):  
Alexandra M Lesenskyj ◽  
Christina R Maxwell ◽  
Shannon Brown ◽  
Ricardo A Cruciani
Keyword(s):  
Neuropathic Pain ◽  
Chronic Neuropathic Pain ◽  
Scrambler Therapy

Treatment of post-herpetic pain with scrambler therapy, a patient-specific neuro-cutaneous electrical stimulation device.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e19564-e19564
Author(s):  
Thomas J. Smith ◽  
Giuseppe Marineo
Keyword(s):  
Neuropathic Pain ◽  
Hematologic Malignancy ◽  
Primary Diagnosis ◽  
Patient Specific ◽  
Treatment Results ◽  
Before And After ◽  
Maximum Pain ◽  
Average Pain ◽  
Average Pain Score ◽  
Scrambler Therapy

e19564^ Background: Post herpetic neuropathy (PHN) is common in cancer and hematologic malignancy patients. It can be debilitating and difficulty to treat effectively. Scrambler therapy, a patient-specific neurocutaneous stimulation device, can be effective in treating chemotherapy induced neuropathy (JPSM 2010) and other neuropathic pain (JPSM 2012). Methods: We treated ten patients, 2 with cancer as their primary diagnosis, with refractory PHN Scrambler therapy at two institutions. Scrambler therapy was given as 30 minute sessions daily for 10 days. Pain was recorded before and after treatment. Results: The patient mean age was 54 ± SD 13 years, 6 men and 4 women, with a mean duration of PHN for 15.6 months (range 2.5 to 48 months) without satisfactory relief despite conventional drugs. The average pain score rapidly diminished from 7.64 ± 1.46 at baseline to 0.42 ± 0.89 at one month, a 95% reduction, with continued relief at 2 and 3 months. Patients achieved maximum pain relief with less than 5 treatments. Conclusions: Scrambler therapy appears to have a promising effect on PHN, with prompt and continued relief and no side effects. Further research is warranted. [Table: see text]

Scrambler therapy efficacy and safety for neuropathic pain correlated with chemotherapy-induced peripheral neuropathy in adolescents: A preliminary study

2018 ◽  
Vol 65 (7) ◽  
pp. e27064 ◽  
Author(s):  
Caterina Tomasello ◽  
Rita Maria Pinto ◽  
Chiara Mennini ◽  
Elena Conicella ◽  
Francesca Stoppa ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Efficacy And Safety ◽  
Therapy Efficacy ◽  
Scrambler Therapy ◽  
Preliminary Study

scholarly journals Scrambler therapy for the treatment of neuropathic pain related to leukemia in a pediatric patient

Medicine ◽  
2017 ◽  
Vol 96 (45) ◽  
pp. e8629 ◽  
Author(s):  
Hahck Soo Park ◽  
Won-Joong Kim ◽  
Hyung Gon Kim ◽  
Seung Hee Yoo
Keyword(s):  
Neuropathic Pain ◽  
Pediatric Patient ◽  
Scrambler Therapy

scholarly journals Case Report: Scrambler Therapy for Treatment-Resistant Central Neuropathic Pain in a Patient with Transverse Myelitis

2019 ◽  
Vol 21 (2) ◽  
pp. 76-80 ◽  
Author(s):  
Maureen A. Mealy ◽  
Scott D. Newsome ◽  
Sharon L. Kozachik ◽  
Michael Levy ◽  
Thomas J. Smith
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Transverse Myelitis ◽  
Central Neuropathic Pain ◽  
The Central Nervous System ◽  
Scrambler Therapy ◽  
Multiple Drugs ◽  
Favorable Safety

Abstract Central neuropathic pain is a severely disabling consequence of conditions that cause tissue damage in the central nervous system. It is often refractory to treatments commonly used for peripheral neuropathy. Scrambler therapy is an emerging noninvasive pain-modifying technique that uses transcutaneous electrical stimulation of nociceptive fibers with the intent of reorganizing maladaptive signaling pathways. It has been examined for the treatment of peripheral neuropathy with favorable safety and efficacy outcomes, but its application to central neuropathic pain has not been reported in transverse myelitis. We describe the use of Scrambler therapy in a patient with persistent central neuropathic pain due to transverse myelitis. The patient had tried multiple drugs for treatment of the pain, but they were not effective or caused adverse effects. After a course of Scrambler therapy, pain scores improved considerably more than what was reported with previous pharmacologic and nonpharmacologic interventions. This case supports further investigation of Scrambler therapy in multiple sclerosis, neuromyelitis optica spectrum disorder, and other immune-mediated disorders that damage the central nervous system.

Sign in / Sign up

Export Citation Format

Share Document